Catherine Gallou

Catherine Gallou is an experienced research scientist with a focus on immuno-oncology and immuno-inflammation. Currently serving as the In Vivo team leader at Servier since January 2018, Catherine previously held the position of R&D project manager at Vaxon Biotech, overseeing preclinical studies for new vaccine candidates from June 2011 to January 2018. Prior roles include leading preclinical studies at SeleXel and postdoctoral positions at Inserm U781, Institut Curie, and Inserm U383. Catherine holds a Doctorate in Molecular Genetics from Université Paris Cité and a DIU in targeted immunotherapies from the University of Lille 1 Sciences and Technology.